ABVC BioPharma, Inc.
ABVC
$1.08
$0.000.00%
| Weiss Ratings | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.97 | |||
| Price History | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.94% | |||
| 30-Day Total Return | -12.50% | |||
| 60-Day Total Return | -30.92% | |||
| 90-Day Total Return | -19.23% | |||
| Year to Date Total Return | -12.50% | |||
| 1-Year Total Return | -84.09% | |||
| 2-Year Total Return | -95.31% | |||
| 3-Year Total Return | -97.69% | |||
| 5-Year Total Return | -99.53% | |||
| 52-Week High % Change | -83.44% | |||
| 52-Week Low % Change | 135.94% | |||
| Price | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.60 | |||
| 52-Week Low Price | $0.67 | |||
| 52-Week Low Price (Date) | Oct 06, 2023 | |||
| 52-Week High Price (Date) | May 09, 2023 | |||
| Valuation | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.43M | |||
| Enterprise Value | 12.48M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.57 | |||
| Earnings Per Share Growth | -50.72% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 43.43 | |||
| Price/Book (Q) | 0.93 | |||
| Enterprise Value/Revenue (TTM) | 123.29 | |||
| Price | $1.05 | |||
| Enterprise Value/EBITDA (TTM) | -2.30 | |||
| Enterprise Value/EBIT | -2.29 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (510)-668-0881 | |||
| Address | 44370 Old Warm Springs Boulevard Fremont, CA 94538 | |||
| Website | www.abvcpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -5,387.86% | |||
| Profit Margin | -6,895.47% | |||
| Management Effectiveness | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -42.67% | |||
| Return on Equity | -- | |||
| Income Statement | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 152.50K | |||
| Total Revenue (TTM) | 152.50K | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | -149.60K | |||
| EBITDA (TTM) | -8.19M | |||
| EBIT (TTM) | -8.22M | |||
| Net Income (TTM) | -10.52M | |||
| Net Income Avl. to Common (TTM) | -10.52M | |||
| Total Revenue Growth (Q YOY) | -99.63% | |||
| Earnings Growth (Q YOY) | 26.02% | |||
| EPS Diluted (TTM) | -2.57 | |||
| EPS Diluted Growth (Q YOY) | 68.02% | |||
| Balance Sheet | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 139.50K | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 1.66M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 8.13M | |||
| Current Ratio (Q) | 0.279 | |||
| Book Value Per Share (Q) | $1.06 | |||
| Total Assets (Q) | 14.49M | |||
| Total Current Liabilities (Q) | 5.93M | |||
| Total Debt (Q) | 2.45M | |||
| Total Liabilities (Q) | 6.36M | |||
| Total Common Equity (Q) | 8.39M | |||
| Cash Flow | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -360.20K | |||
| Cash from Financing (TTM) | 3.92M | |||
| Net Change in Cash (TTM) | -675.00K | |||
| Levered Free Cash Flow (TTM) | -3.05M | |||
| Cash from Operations (TTM) | -4.24M | |||
